Plain-English translation of NCT06096857 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new topical treatment called Roseomonas mucosa combined with ground cardamom seeds for people with atopic dermatitis (eczema). You would apply this medication to your skin a few times per week for 14 weeks, then stop treatment and be monitored for another 14 weeks to see how long the benefits last. The researchers believe this treatment may help reduce itching, rash, and other eczema symptoms.
Current eczema treatments don't work well enough for everyone, and many people struggle with side effects or flare-ups. This study is exploring whether the medication—which uses beneficial bacteria that naturally colonize skin—could offer lasting relief by actually improving the skin's own microbiome rather than just covering up symptoms.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication or a placebo (a non-active control). Twice or three times per week for 14 weeks, you will mix the product with water and apply it to your skin. Throughout the study, you'll complete questionnaires about itching, rash severity, and how the treatment affects your daily life, and the researchers may check your skin's microbiome. After the 14 weeks of treatment, you'll stop using the product but continue check-ins for another 14 weeks to see how long the benefits last.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States